타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Opdivo (nivolumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
Overview Company | Roche / Genentech | Bristol Myers Squibb | AstraZeneca | Roche / Genentech | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | VEGF-A | PD-1 | PD-L1 | PD-L1 | HER2 |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | High DAR (~8), bystander effect, HER2-low activity |
Positioning Known limitation | downregulation across different drug combinations | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | escape detection by the immune system | resistance to existing therapies | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. |
Positioning Development positioning | — | — | — | — | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer |
Technology Payload | — | — | — | — | DXd (topo-I inhibitor) |
Technology Linker | — | — | — | — | Cleavable tetrapeptide |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). |
Toxicology Species | — | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse | Cynomolgus monkey, NHP, Rat, Hamster |
Toxicology Animal (cat.) | — | NHP | — | — | NHP |
Toxicology Major finding | — | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Toxicology CRS | — | N/A (checkpoint inhibitor) | N/A | N/A | Minimal |
Toxicology NOAEL | — | — | — | — | 10 mg/kg |
Clinical Safety signal | — | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Clinical Selected reported efficacy | — | — | — | — | ORR 87% |
Clinical Reported ORR | — | — | — | — | 87% vs 81% (THP) |
Clinical Reported PFS | — | — | — | — | 40.7 months vs 26.9 months (THP) |
Clinical Reported OS | — | — | — | — | Immature at the reported PFS analysis |
Clinical Result source | — | — | — | — | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | — | — | — | NCT04784715 |
Preclinical Animal (cat.) | — | — | — | — | Human, Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Opdivo (nivolumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
Overview Company | Roche / Genentech | Bristol Myers Squibb | AstraZeneca | Roche / Genentech | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | VEGF-A | PD-1 | PD-L1 | PD-L1 | HER2 |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | High DAR (~8), bystander effect, HER2-low activity |
Positioning Known limitation | downregulation across different drug combinations | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | escape detection by the immune system | resistance to existing therapies | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. |
Positioning Development positioning | — | — | — | — | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer |
Technology Payload | — | — | — | — | DXd (topo-I inhibitor) |
Technology Linker | — | — | — | — | Cleavable tetrapeptide |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). |
Toxicology Species | — | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse | Cynomolgus monkey, NHP, Rat, Hamster |
Toxicology Animal (cat.) | — | NHP | — | — | NHP |
Toxicology Major finding | — | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Toxicology CRS | — | N/A (checkpoint inhibitor) | N/A | N/A | Minimal |
Toxicology NOAEL | — | — | — | — | 10 mg/kg |
Clinical Safety signal | — | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Clinical Selected reported efficacy | — | — | — | — | ORR 87% |
Clinical Reported ORR | — | — | — | — | 87% vs 81% (THP) |
Clinical Reported PFS | — | — | — | — | 40.7 months vs 26.9 months (THP) |
Clinical Reported OS | — | — | — | — | Immature at the reported PFS analysis |
Clinical Result source | — | — | — | — | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | — | — | — | NCT04784715 |
Preclinical Animal (cat.) | — | — | — | — | Human, Mouse, In vitro |
추천 비교
추천 비교